Computational cancer neoantigen prediction: current status and recent advances [0.03%]
计算性癌症新抗原预测：现状与近期进展
G Fotakis,Z Trajanoski,D Rieder
G Fotakis
Over the last few decades, immunotherapy has shown significant therapeutic efficacy in a broad range of cancer types. Antitumor immune responses are contingent on the recognition of tumor-specific antigens, which are termed neoantigens. Tum...
L M Roelofsen,P Kaptein,D S Thommen
L M Roelofsen
Immune checkpoint blockade (ICB) unleashes immune cells to attack tumors, thereby inducing durable clinical responses in many cancer types. The number of patients responding to ICB is modest, however, and combination treatments are likely n...
L Chocarro,E Blanco,H Arasanz et al.
L Chocarro et al.
Lymphocyte-activated gene 3 (LAG-3) is a cell surface inhibitory receptor and a key regulator of immune homeostasis with multiple biological activities related to T-cell functions. LAG-3 is considered a next-generation immune checkpoint of ...
Trieu My Van,Christian U Blank
Trieu My Van
Characterization of spatial protein expression for multiple targets from a single tissue is difficult to perform, especially due to the limitations of multiplex immunohistochemistry and tissue heterogeneity. Therefore, a new technology is r...
John B Haanen
John B Haanen
Oliver Nussbaumer,Michael Koslowski
Oliver Nussbaumer
The recent successes of chimeric antigen receptor T cells in the treatment of hematological malignancies have clearly led to an explosion in the field of adoptive cell therapy for cancer. Current efforts are focused on the translation of th...
Gene editing: Towards the third generation of adoptive T-cell transfer therapies [0.03%]
基因编辑：朝向第三代过继T细胞治疗技术发展
Cristina Puig-Saus,Antoni Ribas
Cristina Puig-Saus
First-generation adoptive T-cell transfer (ACT) administering tumor-infiltrating lymphocytes (TILs), and second-generation ACT using autologous T cells genetically modified to express tumor-specific T-cell receptors (TCRs) or chimeric antig...
Tumour mutational burden: primary versus metastatic tissue creates systematic bias [0.03%]
原发与继发肿瘤的突变负荷差异导致系统偏差问题
Desiree Schnidrig,Samra Turajlic,Kevin Litchfield
Desiree Schnidrig
Tumour mutational burden (TMB) has emerged as a reproducible biomarker to predict immunotherapy response across multiple cancer types. However, a key aspect of TMB measurement that is often overlooked is the source of tissue sample used, wh...
Driving innovation for rare skin cancers: utilizing common tumours and machine learning to predict immune checkpoint inhibitor response [0.03%]
利用常见肿瘤和机器学习预测免疫检查点抑制剂反应以推动罕见皮肤癌的创新治疗
J S Hooiveld-Noeken,R S N Fehrmann,E G E de Vries et al.
J S Hooiveld-Noeken et al.
Metastatic Merkel cell carcinoma (MCC) and cutaneous squamous cell carcinoma (cSCC) are rare and both show impressive responses to immune checkpoint inhibitor treatment. However, at least 40% of patients do not respond to these expensive an...
Quantitative RNA assessment and long-term stability in the FFPE tumor samples using Digital Spatial Profiler [0.03%]
使用数字空间分析法在福尔马林固定石蜡包埋的肿瘤样本中进行定量RNA检测及长期稳定性评估
S Gupta,T Chen,B Destenaves
S Gupta
Background: Long-term storage of tissue slides has been reported to induce reduced biomarker (e.g. proteins and messenger RNA) detection. This study aimed to evaluate the impact of long-term storage time (0, 16, 24 and 36...